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Summary P-2 microglobulin levels were measured in stored serum taken at presentation from 262 patients
treated with combination chemotherapy for Kiel classification high-grade lymphoma at a single centre over a
15 year period. A significant association was found between elevated levels and advanced (Ann Arbor stage III
or IV) disease or hepatic infiltration, but not with other sites of extranodal involvement or bulky disease. Patients with normal levels at presentation had a 70% remission rate with treatment compared to 37% of
those with elevated levels (P<0.001). With median follow up of 6 years duration of remission was significantly greater in patients with normal P-2 microglobulin at presentation (plateau at 70%, compared to
median remission of 19 months in those with raised levels, P<0.001). Survival overall was also better in the
group with normal levels (actuarial median 9 years compared to 1 year, P<0.001). Multivariate analyses including treatment type, age, sex, B symptoms, stage, bulk, albumin, sodium, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase and P-2 microglobulin, placed P-2 microglobulin among the three
most influential independent variables for prediction of response rate, duration of remission and overall
survival.
In almost two decades since the initial reports of long-term
disease free survival after chemotherapy for the diffuse agg-
ressive lymphomas (Levitt et al., 1972; De Vita et al., 1975) a
variety of newer, more complex and more toxic regimens
have been described which are said to improve remission
rates and survival (Schein et al., 1976; Laurence et al., 1982;
Fisher et al., 1983; Skarin et al., 1983; Klimo & Connors,
1985). The evaluation of such claims is however made
difficult by the heterogeneity of the patient populations
studied and lack of a well recognised set of prognostic fac-
tors. The recent introduction of yet more intensive consolida-
tion with autologous bone marrow support (Applebaum et
al., 1978; Philip et al., 1985; Armitage et al., 1986; Takvorian
et al., 1987; Goldstone et al., 1988) has made the
identification of such factors more pressing still, to allow
some judgement of the likelihood of recurrence after conven-
tional treatment and hence the rationale for ablative proce-
dures.
In the search for prognostic factors it has been suggested
that serum ,-2 microglobulin may be a useful indicator of
disease extent and activity in lymphomas, although the
results have not been uniform. As the light chain common to
the major histocompatability (HLA) antigens A, B and C
(Cresswell et al., 1974) it is shed into the circulation at a rate
determined by lymphocyte activation and proliferation (Azo-
car et al., 1982). Studies in multiple myeloma have confirmed
its usefulness as an independent prognostic marker (Bataille
et al., 1983) whilst in non-Hodgkin's lymphoma levels have
been correlated with extent of disease, response to chemo-
therapy and survival (Spati et al., 1978; Child et al., 1980;
Hagberg et al., 1983; Legros et al., 1987). Recently it has
been suggested that a serologic staging system based upon
P-2 microglobulin and lactate dehydrogenase (LDH) levels
may identify sub-groups with differing disease-free and over-
all survival more distinctly than conventional staging by the
Ann Arbor criteria (Swan et al., 1989).
The aim of this study was to measure P-2 microglobulin
levels in stored serum from patients treated at St Bar-
tholomew's Hospital for high-grade non-Hodgkin's lympho-
ma (Kiel classification) over a 15 year period, and to relate
these to the outcome of treatment.
Patients and methods
Between January 1975 and December 1990, 338 previously
untreated adult patients with high-grade non-Hodgkin's lym-
phoma received treatment with combination chemotherapy at
St Bartholomew's Hospital. All patients had the diagnosis
confirmed by biopsy and all histology was graded according
to the Kiel classification.
Staging was carried out according to conventional criteria
based upon the Ann Arbor classification (Carbone et al.,
1971). In all cases clinical examination was accompanied by full blood count and biochemical screen of renal and hepatic function, bone marrow aspirate and trephine biopsy, exam-
ination of the cerebrospinal fluid and chest X-ray. The
majority of patients also underwent computed tomographic scanning. Magnetic resonance imaging, ultrasonography,
lymphangiography and radionuclide bone scans were per- formed as clinically indicated. Extranodal lymphoma was
designated as stage Ie or Ile if involving a single extranodal
site or contiguous with a known nodal site, but stage IV if
more extensive. Disease bulk was assessed in a retrospective
analysis of the case records and imaging studies: 303 records
were available for review but for the remaining 35 cases no
definitive statement could be made as to whether a mass of at
least 10 cm diameter (or one third of the thoracic diameter in
the case of mediastinal masses) was present. The clinico-
pathological characteristics of the patients are shown in
Table I.
Patients had blood taken at presentation for the storage of
serum. This was separated by centrifugation on the day of
venesection and stored at - 40°C until defrosting. ,-2 micro-
globulin levels were measured in newly-thawed serum by
double antibody radioimmunoassay (Pharmacia Diagnostics AB, Uppsala, Sweden). The assays were performed in dup- licate and the mean value determined. Where the two levels
diverged by more than 5% a third assay was performed and
the mean taken of the two closest results. The assay has a
sensitivity of 0.15 mg 1'- with an upper limit of normal of
3.0 mg I'. P-2 microglobulin was measured in serum from
262 of the patients treated with chemotherapy. Seventy-six
patients did not have a sample stored. None of the clinico-
pathologic characteristics of these patients differed signifi-
cantly from those ofthe patient population as a whole (Table
I).
All but four patients in whom P-2 microglobulin levels
were measured received anthracycline and alkaloid-based
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Table I Clinico-pathologic characteristics of patients
Patients for whom
P2M was measured
(%)
Total
Males
Age Range
Median
Over 60
B-symptoms
Stage
I
le
II
IIe
III
IV
Bulk (Lymphoma mass > 10 cm)
Bone marrow involved
Extra-nodal lymphoma
Histology (Kiel classification)
Centroblastic
Immunoblastic
High-Grade T-cell
Lymphoblastic B-cell
Lymphoblastic T-cell
Lymphoblastic unclassified
Large cell anaplastic (Ki 1 +)
Sclerosing Mediastinal B-cell
T-cell rich B-cell
High-Grade unclassified
262
156
15-84
55
97
142
5
17
32
27
37
144
81 of 240
46
188
107
50
19
12
9
3
13
14
4
31
76
60 45
17-93
59
37 33
54 45
2
6
12
10
14
55
32
18
72
41
19
7
5
3
1
S
5
2
12
3
4
10
12
7
40
14 of 63
14
56
23
21
6
3
1
0
3
5
0
14
combination chemotherapy in one of several phase II studies
carried out during this period. (The treatment regimens used
are shown in Table II). One patient received only palliative
treatment and three received initial radiotherapy followed by
a combination of adriamycin, vincristine, prednisolone and
L-asparaginase.
Re-evaluation was carried out at the end of chemotherapy
by repeating the tests which had previously been abnormal.
A complete response (CR) was defined as the disappearance
of all clinical, laboratory and radiographic evidence of lym-
phoma. Responding patients with minimal residual radio-
graphic abnormalities were classified as showing good partial
response (GPR). Lesser objective responses were classified as
poor partial response (PPR). Duration of remission for
patients reaching clinical remission (CR or GPR) was mea-
sured from the date of determination of response.
Levels of P-2 microglobulin in different groups were com-
pared using the Mann-Whitney U test, and the proportions
of patients with elevated levels compared by the x2 test.
Univariate analysis of prognostic factors was carried out
both by the log-rank test with groups separated by the
normal range for continuous variables and by use of a
Table II Chemotherapy protocols used: All patients received
prophylactic central nervous system treatment with intrathecal
methotrexate
Name Number treated Percentage
Cyclophosphamide/Doxorubicin, 148 57
Vincristine/Prednisolone
(CHOP) 3 weekly with or without
Methotrexate (350 mgm-2)
Vincristine/Prednisolone 23 10
/Doxorubicin/L-asparaginase
(OPAL) 3 weekly
12 week combination regimen 87 33
comprising:
Cyclophosphamide/Doxorubicin
/Etoposide/Vincristine/Bleomycin
/Prednisolone
univariate Cox model with logarithmic transformation for
non-normal distributions. Multivariate analyses were per-
formed using Cox multiple regression for both dichotomised
and transformed variables for duration of remission and
survival, and logistic regression for response to treatment.
Variables were selected using the 'branch and bound' techni-
que, with variables significant at the 5% level retained in the
model at each step (Cox, 1972).
Results
The mean level of P-2 microglobulin at presentation was
3.85 mg 1` (range 0.51 to 25.24 mg -', with a standard
deviation of 3.16). One hundred and twenty patients (46%)
had levels greater than the upper limit of normal (3.0 mg 1-l).
Fourteen patients with elevated levels of P-2 microglobulin
had evidence of significant renal impairment at presentation
with serum creatinine greater than 150 jmol I'. Since re-
duced renal clearance results in falsely high levels (Schardjin
& Van Eps, 1987) these patients were excluded from further
analyses.
The P-2 microglobulin levels were tested for evidence of
degradation during storage by analysing mean levels for each
year of presentation. The means did not show significant
variation over the 15 years (by F test of one-way variance).
The levels of P-2 microglobulin at presentation correlated
with the Ann Arbor stage of disease: Median levels varied
significantly between the stages, being higher in patients with
more advanced disease (P<0.01). With higher stage disease
a greater proportion of patients had elevated levels (P=
0.025). These results are shown in Figure 1. There was
considerable overlap between patients in stages I and II, and
between stages III and IV both in terms of median levels and
proportions of patients with raised levels. There was no
significant difference in the median levels between patients
with disease stages I and II or between stages III and IV.
Bulky disease did not correlate with raised ,-2 micro-
globulin levels: 44 of 133 patients with normal levels (33%)
had lymphoma masses of 10 cm diameter or more, compared
to 31 of 95 with elevated levels (33%). The overall prevalence
of extranodal lymphoma was the same in patients with nor-
Patients without
P2M available
(%)
59
43
59
4
5
13
16
10
53
22
18
74
30
28
8
4
1
0
4
7
0
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Figure 1 Proportion of patients with elevated levels of P-2
microglobulin at presentation according to Ann Arbor stage.
mal or elevated levels, but analysis by site showed that
patients with high levels were significantly more likely to
have spread to the liver (P<0.001) (Figure 2). A non-
significant trend in favour of bone marrow and pulmonary
infiltration was also seen among patients with raised levels,
but the opposite trends were found for gastrointestinal, bony
and skin involvement, resulting in the overall finding of no
difference when all sites were considered together.
There was no evidence to suggest that particular his-
tological subtypes or immunophenotypes were associated
with high levels: the proportion of patients with elevated
levels in each sub-type did not differ from that of the group
as a whole.
The outcome of chemotherapy correlated with initial 13-2
microglobulin: 70% of those with normal levels reached
clinical remission, as compared to only 37% of those with
elevated levels (P<0.001) (Figure 3).
With an overall median follow-up time of 6 years, for the
138 patients entering clinical remission the disease-free inter-
val was significantly longer for those who had an initially
normal 13-2 microglobulin. The median duration of remission
in the normal group was over 6 years, compared to 19
months for those with elevated levels (P<0.001). There was
a marked difference between the two groups in number of
long term survivors free from recurrence: The group with
normal levels had 70% of patients remaining free from
disease at 6 years compared to only 35% of those with high
levels, (Figure 4). This distinction arose principally from the
difference in rates of recurrence (24% vs 56%) rather than
deaths in remission from other causes.
Overall survival (Figure 5) was also better in the group
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Figure 3 Outcome of therapy in groups with normal or raised
P-2 microglobulin levels.
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Figure 4 Percentage of patients remaining in remission accor-
ding to initial 13-2 microglobulin level.
with normal 13-2 microglobulin at presentation (P<0.01).
These patients showed a median survival time of over 6 years
compared to 1 year for the group with raised levels.
Multivariate analyses were conducted to examine the fac-
tors predictive of response to chemotherapy, duration of
remission and overall survival. For 229 patients complete
data was available for the following factors at presentation:
age, sex, B symptoms, Ann Arbor stage, disease bulk, treat-
ment, serum albumin, sodium, alkaline phosphatase, aspart-
ate aminotransferase and 13-2 microglobulin. Levels of lactate
dehydrogenase were available for a sub-group of 156 pa-
tients. The results of the analyses using dichotomised vari-
ables are shown in Table MI. (These were not substantially
altered by using continuous variables with logarithmic trans-
formation). 13-2 microglobulin was included in the final
models for all three analyses, and the models diverged
significantly from those including all factors if the 13-2 micro-
globulin was excluded. The impact of lactate dehydrogenase
was analysed in the smaller group for which levels were
available but it was not found to be independently prognos-
tic.
Figure 2 Proportion of patients with extranodal spread in
groups with normal or elevated fr2 microglobulin.
30 Discussion
The diffuse aggressive non-Hodgkin's lymphomas (High-
grade-NHL in the Kiel classification, Groups E to J in the
Working Formulation) were first shown to be curable nearly
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Figure 5 Percentage of patients surviving according to initial P-2
microglobulin level.
two decades ago (Levitt et al., 1972; De Vita et al., 1975).
The use of anthracycline-based four-drug chemotherapy regi-
mens such as CHOP (cyclophosphamide, doxorubicin, vin-
cristine and prednisolone) has resulted in long-term disease-
free survival for a substantial minority of patients (McKelvey
et al., 1975; Coltman et al., 1986), whilst more complex and
toxic regimens using larger numbers of drugs have been
apparently more effective when judged against historical con-
trols (Schein et al., 1976; Laurence et al., 1982; Fisher et al.,
1983; Skarin et al., 1983; Klimo & Connors, 1985). The
results with such regimens used at different institutions have
however rarely matched those of their originators (Schneider
et al., 1990; Weick et al., 1991) and phase III trials of direct
comparison have failed to demonstrate a clear advantage for
the more complex treatments (O'Connell et al., 1984; Gordon
et al., 1989).
Several confounding factors make these results difficult to
interpret: The treatment given may differ from that planned,
and reductions in dose intensity, particularly frequent for
older patients receiving complex regimens, may compromise
cure rates (Dixon et al., 1986). The extent of experience at a
particular centre may also influence outcome (Browne et al.,
1986), but probably the greatest variability lies in the patient
populations studied. The lack of a comprehensive set of
prognostic factors which can be applied objectively for
stratification makes even the results of randomised trials
suspect, whilst historical controls are less reliable still.
The increasing application of intensive consolidation of
remission by ablative treatment with autologous stem-cell
support (Applebaum et al., 1978; Philip et al., 1985; Armi-
tage et al., 1986; Takvorian et al., 1987; Goldstone et al.,
1988) has heightened the importance of identifying those
patients for whom the risk of recurrence is high. Whereas
previously all patients reaching remission would be observed
without further treatment, there are now therapeutic as well
as prognostic implications in the analysis. For high-risk
patients these treatments may offer a sign,ificant improvement
in survival, whilst for those already likely to be cured aggres-
sive regimens represent only the chance of further toxicity
and morbidity. Once again prognostic factors capable of
discriminating such groups still require definition themselves.
Previous studies in non-Hodgkin's lymphoma have shown
a correlation between stage of disease and P-2 microglobulin
level (Spati et al., 1978; Child et al., 1980; Hagberg et al.,
1983; Legros et al., 1987) - a finding confirmed here. In these
patients the P-2 microglobulin varied significantly with Ann
Arbor stage although the levels for stages I and II showed
considerable overlap, as did those for stages III and VI. P-2
microglobulin may represent an alternative measure of tu-
mour burden which, while broadly in agreement with con-
ventional staging, nonetheless discriminates slightly different
populations.
The finding that bulky tumour masses and the presence of
extranodal disease per se did not correlate with raised P-2
microglobulin is at odds with the findings of Swan et al.
(Swan et al., 1989) who found a strong correlation between
P-2 microglobulin and tumour burden assessed according to
the M.D. Anderson scoring system. It seems likely that the
association between raised levels and hepatic, bone marrow
or pulmonary disease reflects the greater tumour burden
when these sites are affected, as compared to skin, gas-
trointestinal tract or central nervous system involvement
when the number of lymphoma cells present may be much
fewer.
In keeping with the findings of Legros (Legros et al., 1987)
it appears that the response to chemotherapy may be at least
partly predicted by P-2 microglobulin. The much higher
clinical remission rate seen in those with normal levels may
relate to retention of surface major histocompatability com-
plex (MHC) epitopes on the tumour cells of those patients
with lower 13-2 microglobulin, enabling more effective recog-
nition of tumour-specific antigens by cytotoxic T-cells. In
support of this is the finding that lymphomas with absent
MHC class I expression have a particularly poor prognosis
(Moller et al., 1986), and that changes in HLA complex
proteins which impair light and heavy chain association
result in enhanced release of P-2 microglobulin (Ferrier et al.,
1985; Rein et al., 1987).
The considerably lower risk of recurrence and longer dura-
tion of remission in patients with normal P-2 microglobulin
levels also accord with the results of previous smaller studies
(Hagberg et al., 1983). Once again it may be postulated that
this relates to the effectiveness of host immune surveillance.
The overall survival differences are also in agreement with
previous reports (Legros et al., 1987; Han et al., 1989). The
finding that 13-2 microglobulin remained an independent
prognostic factor in multivariate analysis provides further
confirmation of its potential in this group of diseases, with
the possibility in future for derivation of a serologic staging
Table III Results of multivariate analyses using variables dichotomised
Coefficient/Standard error P
Response to chemotherapy:
Albumin (below 36 gl-') - 2.530 0.012
P2-microglobulin (above 3.0mg ') - 2.054 0.041
Stage IV disease - 2.073 0.039
Bulk disease - 1.905 0.058
Duration of remission:
P2 microglobulin (above 3.0mgl1') 3.542 0.001
Albumin (below 35 g1-') 2.764 0.007
Treatment with OPAL (Lymphoblastic) - 2.154 0.033
Overall survival:
Albumin (below 35 g 1) 5.558 <0.0001
P2 microglobulin (above 3.0mgl1') 4.026 <0.0001
Alkaline phosphatase (below 115 iu -') - 2.354 0.019796 P.W.M.JOHNSON et al.
system to replace the increasingly outmoded Ann Arbor
classification.
The finding that albumin was of equivalent but indepen-
dent prognostic significance in these patients reflects its posi-
tion as an indirect measure of their general condition at
presentation, which might be expected to parallel perfor-
mance status, had this been available. The implication from
this analysis is that the combination of patient-related albu-
min and disease-related ,-2 microglobulin is the most useful
set of factors to analyse. Other studies may find different
factors of importance within these two categories, and in this
context the results of the international collaborative inves-
tigation of prognostic factors already underway will be
eagerly awaited.
In conclusion, P-2 microglobulin is an independent prog-
nostic factor for response to treatment, duration of remission
and survival in patients with diffuse aggressive non-Hodg-
kin's lymphomas. It remains significant in multivariate analy-
ses and in the future prospective studies should be performed
to validate these observations. Whilst it is inevitable that
prognostic factors are of relevance in inverse proportion to
the efficacy of treatment, it may be that the derivation of a
reproducible prognostic index will in turn help the
identification of more effective regimens.
The authors are pleased to thank the Department of Radiology at St
Bartholomew's Hospital for the many imaging studies carried out
during the management of these patients, and the medical house staff
and nursing staff on the medical oncology wards for their dedicated
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